Vivesto Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Vivesto's earnings have been declining at an average annual rate of -5.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 18.3% per year.
Belangrijke informatie
-5.9%
Groei van de winst
8.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 0.7% |
Inkomstengroei | -18.3% |
Rendement op eigen vermogen | -55.3% |
Nettomarge | -1,496.7% |
Volgende winstupdate | 21 Nov 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Vivesto geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 7 | -99 | 57 | 0 |
31 Mar 24 | 7 | -117 | 73 | 0 |
31 Dec 23 | 7 | -129 | 84 | 0 |
30 Sep 23 | 2 | -284 | 87 | 0 |
30 Jun 23 | 3 | -340 | 93 | 0 |
31 Mar 23 | 3 | -351 | 95 | 0 |
31 Dec 22 | 3 | -357 | 96 | 0 |
30 Sep 22 | 13 | -140 | 101 | 0 |
30 Jun 22 | 24 | -99 | 107 | 0 |
31 Mar 22 | 29 | -118 | 111 | 0 |
31 Dec 21 | 29 | -133 | 124 | 0 |
30 Sep 21 | -184 | -348 | 88 | 0 |
30 Jun 21 | -195 | -354 | 108 | 0 |
31 Mar 21 | -199 | -376 | 146 | 0 |
31 Dec 20 | 4 | -210 | 185 | 0 |
31 Oct 20 | 205 | -59 | 83 | 0 |
31 Jul 20 | 205 | -24 | 73 | 0 |
30 Apr 20 | 206 | -11 | 226 | 0 |
31 Jan 20 | 4 | -196 | 113 | 0 |
31 Oct 19 | 6 | -167 | 85 | 0 |
31 Jul 19 | 9 | -210 | 60 | 0 |
30 Apr 19 | 10 | -201 | 52 | 0 |
31 Jan 19 | 14 | -154 | 107 | 0 |
31 Oct 18 | 13 | -153 | 106 | 0 |
31 Jul 18 | 13 | -117 | 106 | 0 |
30 Apr 18 | 12 | -118 | 109 | 0 |
31 Jan 18 | 10 | -128 | 115 | 0 |
31 Oct 17 | 10 | -139 | 126 | 0 |
31 Jul 17 | 8 | -155 | 135 | 0 |
30 Apr 17 | 7 | -160 | 139 | 0 |
31 Jan 17 | 7 | -151 | 139 | 0 |
31 Oct 16 | 16 | -137 | 141 | 0 |
31 Jul 16 | 19 | -139 | 148 | 0 |
30 Apr 16 | 23 | -142 | 156 | 0 |
31 Jan 16 | 26 | -139 | 150 | 0 |
31 Oct 15 | 18 | -141 | 136 | 0 |
31 Jul 15 | 19 | -124 | 122 | 0 |
30 Apr 15 | 19 | -117 | 111 | 0 |
31 Jan 15 | 23 | -125 | 123 | 0 |
31 Oct 14 | 26 | -128 | 129 | 0 |
31 Jul 14 | 28 | -120 | 124 | 0 |
30 Apr 14 | 30 | -105 | 120 | 0 |
31 Jan 14 | 30 | -90 | 109 | 0 |
Kwaliteitswinsten: VIVE is currently unprofitable.
Groeiende winstmarge: VIVE is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: VIVE is unprofitable, and losses have increased over the past 5 years at a rate of 5.9% per year.
Versnelling van de groei: Unable to compare VIVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: VIVE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: VIVE has a negative Return on Equity (-55.26%), as it is currently unprofitable.